Biogen’s inherited eye disease gene therapy misses the mark in late-stage trial
Gene therapy was being evaluated for the treatment of the rare eye disease choroideremia
Imbruvica/Venclyxto tops Gazyva plus chemo in first-line CLL/SLL
Imbruvica treatment regimen demonstrated superior progression-free survival compared to Gazyva combo
AZ, Pfizer/BioNTech vaccines ‘highly effective’ against Delta variant
New real world data from PHE shows vaccines can protect against hospitalisation caused by variant
Novavax’s COVID-19 vaccine shows 90% efficacy in Phase III
Jab was also found to be 100% effective at preventing moderate to severe COVID-19
Opdivo plus Yervoy scores NICE backing for certain bowel cancer patients
Immunotherapy combo approved for the treatment of advanced bowel cancer patients with rare MSI-H/dMMR mutations
Vertex, CRISPR Therapeutics’ blood disorder gene therapy shows more promise
CTX001 is being evaluated as a one-time treatment for transfusion dependent beta thalassemia and sickle cell disease
NICE to reassess Kyowa Kirin’s Poteligeo
An appeal lodged by the company and various charities has been upheld by an independent appeal panel
UK to donate 100 million surplus COVID-19 vaccine doses
Gov’t will donate five million of the surplus doses by the end of September
New hybrid healthcare agency Stirred launches
Stirred has been launched this week by former senior Pegasus colleagues Jo Spadaccino and Stuart Hehir
Novartis' oral therapy iptacopan shows promise in PNH
Majority of patients were transfusion-free through 12 weeks of study, according to the new data
Modus Therapeutics partners with Imperial College London on malaria drug
Collaboration will research the effects of Modus' drug sevuparin in patients with severe malaria
MHRA approves Venclyxto for newly diagnosed AML
The approval is based on results from the Phase III VIALE-A study as well as the Phase Ib M14-358 clinical trial
NICE broadens access to treatments for rheumatoid arthritis
New guidance enables earlier access to certain treatments, including biologics
Patient Partnership Index 2021 - results announced!
Three Gold Standards awarded for partnership work in patient advocacy and communications
Cell and Gene Therapy Catapult forms consortium of over 20 organisations
Consortium will assess multiple process analytical technologies used in the cell and gene therapy industry
Bayer subsidiary doses first patient with Parkinson’s disease cell therapy
German pharma company announces progress in its 'two-pronged' cell and gene therapy approach to Parkinson's disease
Opdivo combos show OS benefit in advanced oesophageal cancer
Opdivo plus chemotherapy or Yervoy demonstrated overall survival benefit in PD-L1-positive and all-randomised populations
Astellas’ Xtandi bags NICE approval in prostate cancer
Oral androgen receptor signalling inhibitor now approved to treat metastatic hormone-sensitive prostate cancer
£3m worth of illegally sold meds and devices seized in UK
Under Operation Pangea, officers were also able to shut down or block 113,000 illegally operating websites
Amicus' Pompe disease therapy joins early access scheme
The MHRA has issued an EAMS scientific opinion opening the door to use of cipaglucosidase alfa with miglustat in eligible patients with Pompe disease
PharmaTimes - The latest news in healthcare and life sciences - News RSS
Subscribe to Pharma times RSS Feed feed
